Phase II study of everolimus (EVL) and octreotide (OCT) LAR in patients with non-functioning gastrointestinal neuroendocrine tumours (GI-NETs): EVERLAR study

MLA

Jorge Barriuso, et al. “Phase II Study of Everolimus (EVL) and Octreotide (OCT) LAR in Patients with Non-Functioning Gastrointestinal Neuroendocrine Tumours (GI-NETs): EVERLAR Study.” Annals of Oncology, vol. 27, Oct. 2016, p. vi145. EBSCOhost, https://doi.org/10.1093/annonc/mdw369.29.

APA

Jorge Barriuso, Ignacio Matos, Rocio Garcia-Carbonero, Jose Luis Manzano, E. Dotor, Oriol Casanovas, Jaume Capdevila, C. Lopez, Alexandre Teule, Vicente Alonso, Ana Custodio, R. Salazar, & Daniel Castellano. (2016). Phase II study of everolimus (EVL) and octreotide (OCT) LAR in patients with non-functioning gastrointestinal neuroendocrine tumours (GI-NETs): EVERLAR study. Annals of Oncology, 27, vi145. https://doi.org/10.1093/annonc/mdw369.29

Chicago

Jorge Barriuso, Ignacio Matos, Rocio Garcia-Carbonero, Jose Luis Manzano, E. Dotor, Oriol Casanovas, Jaume Capdevila, et al. 2016. “Phase II Study of Everolimus (EVL) and Octreotide (OCT) LAR in Patients with Non-Functioning Gastrointestinal Neuroendocrine Tumours (GI-NETs): EVERLAR Study.” Annals of Oncology 27 (October): vi145. doi:10.1093/annonc/mdw369.29.